Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022

HEALTH
&
BIOTECHNOLOGY


Financial Post: Skylight Health Group
Rakovina Therapeutics Announces Preclinical Data Presentation...
Skylight Health Announces Strategic Investment from U.S. Institutional Healthcare Firm
Skylight Health to Participate in Medicaid Value-Based Care Model in Colorado
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions


Resverlogix will focus on the prevention and treatment of Post COVID-19 Conditions
Skylight Health Expands Value-Based-Care Plan in Florida


Skylight Health Group NASDAQ:SLHG | TSXV:SLHG - a rapidly growing opportunity in value-based care
Skylight Health Provides Clinical Research Update
Resverlogix Publishes Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease..
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
Rakovina Presents Preclinical Data at the 2022 AACR Special Conference on Sarcomas
Resverlogix Announces Type C Meeting with FDA for Phase 3 High-risk COVID-19 Outpatient Study
Aduro Joins Canada Plastics Pact as a Signatory Partner


InvestmentPitch Media: Rakovina Therapeutics committed to advancing new cancer therapies
Rakovina Presents at the American Association of Cancer Research (AACR) Annual General Meeting..
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal..
Rakovina to Present at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)


Rakovina Therapeutics Inc. TSXV: RKV


The Market Herald: Resverlogix (TSX:RVX) steps up Phase 2b study for COVID-19 treatment


Resverlogix Corp. TSX: RVX


National Post: Rakovina preventing cancer cells from making DNA repairs they need to survive


National Post: Calgary-based biotech firm specializes in instructing cells to fight complex diseases
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 with 1st Site in Brazil and 2nd in Canada
Resverlogix Commences Dosing of Patients in Phase 2b COVID-19 Trial


InvestmentPitch Media: Resverlogix Announces First Patient Dosing for Covid19 Clinical Trials


CEO Clips: Resverlogix (TSX: RVX) | The Future of Drug Development


The Market Herald: Rakovina Therapeutics (TSXV:RKV) partners with St. Baldrick’s Foundation
Rakovina Therapeutics Announces Non-dilutive Financial Contributions....
Resverlogix Announces Corporate Update Webcast and Conference Call
RKV Partners w. St. Baldrick’s Foundation to Research & Develop Treatments for Childhood Bone Cancer
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy
Resverlogix in Active Discussions with The Kingdom of Morroco's Ministry of Health...
Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference
Rakovina Therapeutics Presents at the 2021 AACR- NCI-EORTC Virtual International Conference...
Resverlogix : Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series


Resverlogix: Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot
The Good Shroom Co's Velada Cannabis Brand To be Listed for Sale in Ontario
Rakovina Therapeutics to Present at the AACR-NCI-EORTC International Conference....
The Good Shroom Co Signs Agreement with Rob Leichman of the Lyric Group to Lead its Retail Launch...
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial..


InvestmentPitch Media:The Good Shroom Co contracts to sell its functional beverages through Ecotrend
The Good Shroom Co Signs Contract With Top Tier Canadian Retail Distributor Ecotrend
Rakovina Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
Resverlogix Announces US$6 Million Debenture Financing